What do systematic reviews say?

Summary of Findings Table ‐ IncobotulinumtoxinA 24U vs OnabotulinumtoxinA 24U

It is very uncertain whether summary of Findings Table ‐ IncobotulinumtoxinA 24U changes major adverse events compared with onabotulinumtoxinA 24U (very low certainty).

• Botulinum toxin type A for facial wrinkles 2021 · Cochrane Headline outcomes only
  OR 0.02 [0, 1.77]
  1 study · 381 participants
  Very low

Summary of Findings Table ‐ AbobotulinumtoxinA 50U vs OnabotulinumtoxinA 20U

Summary of Findings Table ‐ AbobotulinumtoxinA 50U showed no clear difference in major adverse events ‐ Any major adverse events (eyelid ptosis,… compared with onabotulinumtoxinA 20U (moderate certainty).

• Botulinum toxin type A for facial wrinkles 2021 · Cochrane Headline outcomes only
  OR 2.65 [0.77, 9.09]
  1 study · 433 participants
  Moderate

Summary of Findings Table ‐ OnabotulinumtoxinA 20U vs placebo

Summary of Findings Table ‐ OnabotulinumtoxinA 20U probably leads to higher major adverse events compared with placebo (moderate certainty).

• Botulinum toxin type A for facial wrinkles 2021 · Cochrane Headline outcomes only
  OR 3.62 [1.5, 8.74]
  8 studies · 1390 participants
  Moderate

Summary of Findings Table ‐ IncobotulinumtoxinA 20U vs placebo

• Botulinum toxin type A for facial wrinkles 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 547 participants
  Moderate

Summary of Findings Table ‐ DaxibotulinumtoxinA 40U vs placebo

• Botulinum toxin type A for facial wrinkles 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 716 participants
  Moderate

Summary of Findings Table ‐ AbobotulinumtoxinA 50U vs placebo

Summary of Findings Table ‐ AbobotulinumtoxinA 50U showed no clear difference in major adverse events (eyelid ptosis, eyelid sensory disorder,… compared with placebo (moderate certainty).

• Botulinum toxin type A for facial wrinkles 2021 · Cochrane Headline outcomes only
  RR 3.36 [0.88, 12.87]
  7 studies · 1294 participants
  Moderate